VANCOUVER, BC, Aug. 15, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended June 30, 2022. “We are pleased to report on another highly productive quarter,” said Filament CEO Benjamin Lightburn.


Previous articleSmall Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction Study
Next articleatai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update